Skip to Main Content

Advertisement

Skip Nav Destination

Issues

Cancer Immunology Research

Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.

Table of Contents

What We're Reading

Meeting Report

Review

Research Articles

RAB21+ABHD12+ sEVs derived from head and neck cancer tumor cells contribute to the formation of the immunosuppressive, premetastatic niche in the lung. Data highlight how sEVs are a potential therapeutic target for enhancing the efficacy of immunotherapy.

HCC is a leading cause of cancer-related death globally and existing immunotherapy is not very effective. The authors report targeting the retinoic acid pathway through RALDH1 inhibition could be a novel immunotherapeutic approach for HCC.

CD137 is a promising target for enhancing cancer immunotherapy. The authors show that the CD137 immune agonist M9657 induces potent mesothelin-dependent antitumor activity without the systemic immune activation seen with CD137 agonist monotherapies.

TCR T-cell therapy has modest therapeutic efficacy against solid tumors. The authors show enhanced ability of TCR T cells to eradicate solid tumors by combination with lymph node–targeted AMP-peptide vaccination in mouse and human models.

The immune landscape of IDH–wild-type, high-grade gliomas is revealed. Key myeloid and T-cell subsets are identified, as well as interactions that impact antitumor immunity in the tumor microenvironment. This study highlights potential therapeutic targets for treating glioma.

The authors identify a novel function for CD99 in inducing tumor cell phagocytosis and reprogramming of macrophages, thus suggesting that agonistic antibodies against CD99 may be exploited to improve immunotherapeutic strategies for EWS.

The virus-like-vesicle, CARG-2020, which combines oncolytic activity with immune-modulatory effects, is demonstrated to remodel the tumor microenvironment. CARG-2020 used as a therapy induces complete tumor regression, generates immune memory, and protects against future tumor recurrence.

Correction

Close Modal

or Create an Account

Close Modal
Close Modal